Cargando…
Prophylactic and Therapeutic Use of Strontium Ranelate Reduces the Progression of Experimental Osteoarthritis
Introduction: Strontium ranelate (SrRan) has the potential to interfere in the progression of osteoarthritis (OA), multifactorial disease associated with mechanical problems and articular inflammatory changes. Objectives: This study aimed to test the effects of prophylactic and therapeutic use of Sr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157419/ https://www.ncbi.nlm.nih.gov/pubmed/30283333 http://dx.doi.org/10.3389/fphar.2018.00975 |
_version_ | 1783358267946172416 |
---|---|
author | Rodrigues, Thiago A. de Oliveira Freire, Abner Carvalho, Heetor C. O. Silva, Gyl E. B. Vasconcelos, José W. Guerra, Rosane N. M. de Sousa Cartágenes, Maria do Socorro Garcia, João B. S. |
author_facet | Rodrigues, Thiago A. de Oliveira Freire, Abner Carvalho, Heetor C. O. Silva, Gyl E. B. Vasconcelos, José W. Guerra, Rosane N. M. de Sousa Cartágenes, Maria do Socorro Garcia, João B. S. |
author_sort | Rodrigues, Thiago A. |
collection | PubMed |
description | Introduction: Strontium ranelate (SrRan) has the potential to interfere in the progression of osteoarthritis (OA), multifactorial disease associated with mechanical problems and articular inflammatory changes. Objectives: This study aimed to test the effects of prophylactic and therapeutic use of SrRan on clinical parameters of pain, the inflammatory process, and degradation of the articular cartilage. Methods: This was an experimental study, using a model of knee OA induced by intra-articular injection of monoiodoacetate. Thirty Wistar rats were divided into five groups and treated as indicated: control, without intervention; prophylactic, received SrRan at a daily oral dose of 250 mg/kg for 28 days before OA induction; SrRan treatments, administered 250 or 500 mg/kg/day for 28 days after the induction; and model control, received saline solution after the induction. Behavioral tests (joint incapacity, mechanical hyperalgesia, tactile sensitivity, and forced ambulation), histological evaluation of articular cartilage, and determination of inflammatory cytokines in the synovial fluid (interleukin [IL]-6, IL-10, tumor necrosis factor [TNF]-α, and interferon [INF]-γ) were performed. Results: Both prophylactic and therapeutic treatments improved the articular discomfort. A prophylactic dose of 500 mg/kg/day also improved mechanical hyperalgesia and the same dose was beneficial on tactile sensitivity. SrRan did not improve ambulation. Levels of IL-6, IL-10, TNF-α, and IFN-γ in SrRan-treated groups with OA were not significantly different compared with those in the normal control animals. The histopathological evaluation showed less articular damage in the SrRan-treated and control groups compared to the saline-treated group. Conclusion: The prophylactic and therapeutic administration of SrRan was associated with improved behavioral patterns of pain, especially joint discomfort. SrRan administration mitigated histological changes in the articular cartilage and reduced the inflammatory process, which beneficially reduced the progression of OA in the experimental model studied. |
format | Online Article Text |
id | pubmed-6157419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61574192018-10-03 Prophylactic and Therapeutic Use of Strontium Ranelate Reduces the Progression of Experimental Osteoarthritis Rodrigues, Thiago A. de Oliveira Freire, Abner Carvalho, Heetor C. O. Silva, Gyl E. B. Vasconcelos, José W. Guerra, Rosane N. M. de Sousa Cartágenes, Maria do Socorro Garcia, João B. S. Front Pharmacol Pharmacology Introduction: Strontium ranelate (SrRan) has the potential to interfere in the progression of osteoarthritis (OA), multifactorial disease associated with mechanical problems and articular inflammatory changes. Objectives: This study aimed to test the effects of prophylactic and therapeutic use of SrRan on clinical parameters of pain, the inflammatory process, and degradation of the articular cartilage. Methods: This was an experimental study, using a model of knee OA induced by intra-articular injection of monoiodoacetate. Thirty Wistar rats were divided into five groups and treated as indicated: control, without intervention; prophylactic, received SrRan at a daily oral dose of 250 mg/kg for 28 days before OA induction; SrRan treatments, administered 250 or 500 mg/kg/day for 28 days after the induction; and model control, received saline solution after the induction. Behavioral tests (joint incapacity, mechanical hyperalgesia, tactile sensitivity, and forced ambulation), histological evaluation of articular cartilage, and determination of inflammatory cytokines in the synovial fluid (interleukin [IL]-6, IL-10, tumor necrosis factor [TNF]-α, and interferon [INF]-γ) were performed. Results: Both prophylactic and therapeutic treatments improved the articular discomfort. A prophylactic dose of 500 mg/kg/day also improved mechanical hyperalgesia and the same dose was beneficial on tactile sensitivity. SrRan did not improve ambulation. Levels of IL-6, IL-10, TNF-α, and IFN-γ in SrRan-treated groups with OA were not significantly different compared with those in the normal control animals. The histopathological evaluation showed less articular damage in the SrRan-treated and control groups compared to the saline-treated group. Conclusion: The prophylactic and therapeutic administration of SrRan was associated with improved behavioral patterns of pain, especially joint discomfort. SrRan administration mitigated histological changes in the articular cartilage and reduced the inflammatory process, which beneficially reduced the progression of OA in the experimental model studied. Frontiers Media S.A. 2018-09-19 /pmc/articles/PMC6157419/ /pubmed/30283333 http://dx.doi.org/10.3389/fphar.2018.00975 Text en Copyright © 2018 Rodrigues, de Oliveira Freire, Carvalho, Silva, Vasconcelos, Guerra, de Sousa Cartágenes and Garcia. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Rodrigues, Thiago A. de Oliveira Freire, Abner Carvalho, Heetor C. O. Silva, Gyl E. B. Vasconcelos, José W. Guerra, Rosane N. M. de Sousa Cartágenes, Maria do Socorro Garcia, João B. S. Prophylactic and Therapeutic Use of Strontium Ranelate Reduces the Progression of Experimental Osteoarthritis |
title | Prophylactic and Therapeutic Use of Strontium Ranelate Reduces the Progression of Experimental Osteoarthritis |
title_full | Prophylactic and Therapeutic Use of Strontium Ranelate Reduces the Progression of Experimental Osteoarthritis |
title_fullStr | Prophylactic and Therapeutic Use of Strontium Ranelate Reduces the Progression of Experimental Osteoarthritis |
title_full_unstemmed | Prophylactic and Therapeutic Use of Strontium Ranelate Reduces the Progression of Experimental Osteoarthritis |
title_short | Prophylactic and Therapeutic Use of Strontium Ranelate Reduces the Progression of Experimental Osteoarthritis |
title_sort | prophylactic and therapeutic use of strontium ranelate reduces the progression of experimental osteoarthritis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157419/ https://www.ncbi.nlm.nih.gov/pubmed/30283333 http://dx.doi.org/10.3389/fphar.2018.00975 |
work_keys_str_mv | AT rodriguesthiagoa prophylacticandtherapeuticuseofstrontiumranelatereducestheprogressionofexperimentalosteoarthritis AT deoliveirafreireabner prophylacticandtherapeuticuseofstrontiumranelatereducestheprogressionofexperimentalosteoarthritis AT carvalhoheetorco prophylacticandtherapeuticuseofstrontiumranelatereducestheprogressionofexperimentalosteoarthritis AT silvagyleb prophylacticandtherapeuticuseofstrontiumranelatereducestheprogressionofexperimentalosteoarthritis AT vasconcelosjosew prophylacticandtherapeuticuseofstrontiumranelatereducestheprogressionofexperimentalosteoarthritis AT guerrarosanenm prophylacticandtherapeuticuseofstrontiumranelatereducestheprogressionofexperimentalosteoarthritis AT desousacartagenesmariadosocorro prophylacticandtherapeuticuseofstrontiumranelatereducestheprogressionofexperimentalosteoarthritis AT garciajoaobs prophylacticandtherapeuticuseofstrontiumranelatereducestheprogressionofexperimentalosteoarthritis |